Journal article Open Access

The Therapeutic Effects of Oral and Transdermal Rivastigmine for the Treatment of Alzheimer's Disease

Gustavo A. A. dos Santos*; Paulo Celso Pardi

Abstract

Objectives: To conduct a preliminary assessment of the effects of the oral and transdermal pharmaceutical forms of rivastigmine tartrate

Methods: Forty patients with AD were treated with cholinesterase inhibitors (ChE-Is), evaluated using the MMSE and NPI, and simultaneously sampled to determine their serum levels of AChE and BuChE for 180 days.

Results: The differences obtained between the oral and transdermal forms, as assessed by the MMSE and NPI scores of the AD patients, were not significantly different at the three time points examined (0, 90, and 180 days). However, the serum BuChE levels of the transdermal group were significantly different (p < 0.0004) than those of the oral group at 90 days.

Conclusion: The use of a transdermal ChE-I, rivastigmine tartrate, significantly reduced the levels of BuChE in the AD patients.

Files (383.6 kB)
Name Size
JPDD-02-0022.pdf
md5:0dc19c0d123aa8dcbb05e1a86a3d0102
383.6 kB Download
47
25
views
downloads
All versions This version
Views 4747
Downloads 2525
Data volume 9.6 MB9.6 MB
Unique views 4343
Unique downloads 2424

Share

Cite as